Literature DB >> 24954414

Relationship between contrast sensitivity test and disease severity in multiple sclerosis patients.

A Soler García1, A González Gómez1, L C Figueroa-Ortiz2, A García-Ben3, J García-Campos4.   

Abstract

OBJECTIVE: To assess the importance of the Pelli-Robson contrast sensitivity test in multiple sclerosis patients according to the Expanded Disability Status Scale (EDSS).
MATERIAL AND METHODS: A total of 62 patients with multiple sclerosis were included in a retrospective study. Patients were enrolled from the Neurology Department to Neuroophthalmology at Virgen de la Victoria Hospital. Patients were classified into 3 groups according to EDSS: group A) lower than 1.5, group B) between 1.5 and 3.5 and group C) greater than 3.5. Visual acuity and monocular and binocular contrast sensitivity were performed with Snellen and Pelli-Robson tests respectively. Twelve disease-free control participants were also recruited. Correlations between parameter changes were analyzed.
RESULTS: The mean duration of the disease was 81.54±35.32 months. Monocular and binocular Pelli-Robson mean values in the control group were 1.82±0.10 and 1.93±0.43 respectively, and 1.61±0.29 and 1.83±0.19 in multiple sclerosis patients. There were statistically significant differences in the monocular analysis for a level of significance P<.05. Mean monocular and binocular Pelli-Robson values in relation to gravity level were, in group A: 1.66±0.24 and 1.90±0.98, group B: 1.64±0.21 and 1.82±0.16, and group C: 1.47±0.45 and 1.73±0.32 respectively. Group differences were statistically significant in both tests: P=.05 and P=.027.
CONCLUSIONS: Monocular and binocular contrast discrimination analyzed using the Pelli-Robson test was found to be significantly lower when the severity level, according EDSS, increases in multiple sclerosis patients.
Copyright © 2013 Sociedad Española de Oftalmología. Published by Elsevier Espana. All rights reserved.

Entities:  

Keywords:  Contrast sensitivity; Escala expandida del estado de discapacidad; Esclerosis múltiple; Expanded disability status scale; Multiple sclerosis; Neuritis óptica; Optic neuritis; Pelli-Robson; Sensibilidad al contraste

Mesh:

Year:  2014        PMID: 24954414     DOI: 10.1016/j.oftal.2014.03.026

Source DB:  PubMed          Journal:  Arch Soc Esp Oftalmol        ISSN: 0365-6691


  5 in total

1.  Retinal nerve fiber layer and ganglion cell layer changes on optical coherence tomography in early multiple sclerosis and optic neuritis cases.

Authors:  Ganesh Pillay; Anita Ganger; Digvijay Singh; Rohit Bhatia; Pradeep Sharma; Vimla Menon; Rohit Saxena
Journal:  Indian J Ophthalmol       Date:  2018-01       Impact factor: 1.848

2.  CAPTCHA as a Visual Performance Metric in Active Macular Disease.

Authors:  Gautam Vangipuram; Aaron Y Lee; Kasra A Rezaei; Lisa C Olmos De Koo; Yewlin E Chee; Jennifer R Chao; Catherine Egan; Cecilia S Lee
Journal:  J Ophthalmol       Date:  2019-06-09       Impact factor: 1.909

3.  Functional Evaluation of the Visual Pathway in Patients with Multiple Sclerosis Using a Multifunction Stimulator Monitor.

Authors:  M Satue; L Jarauta; J Obis; M Cipres; M J Rodrigo; C Almarcegui; I Dolz; J R Ara; J Martin; L E Pablo; E Garcia-Martin
Journal:  J Ophthalmol       Date:  2019-09-18       Impact factor: 1.909

4.  Systemic Mesenchymal Stem Cell Treatment Mitigates Structural and Functional Retinal Ganglion Cell Degeneration in a Mouse Model of Multiple Sclerosis.

Authors:  Oliver W Gramlich; Alexander J Brown; Cheyanne R Godwin; Michael S Chimenti; Lauren K Boland; James A Ankrum; Randy H Kardon
Journal:  Transl Vis Sci Technol       Date:  2020-07-10       Impact factor: 3.283

5.  Evaluation of Retinal Structure and Optic Nerve Function Changes in Multiple Sclerosis: Longitudinal Study with 1-Year Follow-Up.

Authors:  Riwanti Estiasari; Adisresti Diwyacitta; Muhammad Sidik; Ni Nengah Rida Ariarini; Freddy Sitorus; Saraf Shafa Marwadhani; Kartika Maharani; Darma Imran; Reza Aditya Arpandy; David Pangeran; Manfaluthy Hakim
Journal:  Neurol Res Int       Date:  2021-06-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.